Latest & greatest articles for citalopram

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on citalopram or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on citalopram and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for citalopram

1. Citalopram

Citalopram Top results for citalopram - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for citalopram The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial 29783900 2018 05 22 1477-0873 2018 May 01 Clinical rehabilitation Clin Rehabil The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. 269215518777791 10.1177/0269215518777791 The present study aimed to assess (...) the effectiveness of oral citalopram, compared with fluoxetine and a placebo, in patients with post-stroke motor disabilities. A randomized double-blind placebo-controlled clinical trial was conducted between January 2015 and January 2016. The neurology department of a university-affiliated urban hospital in Tehran, Iran. Ninety adult patients with acute ischemic stroke, hemiplegia, or hemiparesis and a Fugl-Meyer Motor Scale score of below 55 were included. Participants were randomly allocated to one of three

EvidenceUpdates2018

3. Citalopram and escitalopram: opt for other SSRI antidepressants

Citalopram and escitalopram: opt for other SSRI antidepressants Prescrire IN ENGLISH - Spotlight ''Citalopram and escitalopram: opt for other SSRI antidepressants'', 1 September 2016 {1} {1} {1} | | > > > Citalopram and escitalopram: opt for other SSRI antidepressants Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Citalopram and escitalopram: opt (...) for other SSRI antidepressants As of early 2016, studies point to the same overall conclusion: that citalopram and its derivative escitalopram expose patients to a higher risk of cardiac disorders than other SSRI antidepressants. Citalopram and escitalopram are selective serotonin reuptake inhibitors (SSRI). These two drugs are no more effective than other SSRI antidepressants, and their adverse effects profile is also very similar. In 2011 and 2012, the Food and Drug Administration (FDA) issued

Prescrire2016

4. Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use

Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use - GOV.UK GOV.UK uses cookies to make the site simpler. Search Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use From: Published: 18 July 2016 Therapeutic area: Possible illicit drug use should be considered (...) when prescribing medicines that have the potential to interact adversely. Contents Suspected drug interaction between citalopram and cocaine We received a that raised concerns about a suspected drug interaction between citalopram and cocaine after the death of a man due to subarachnoid haemorrhage. The case was discussed by the UK Commission on Human Medicine’s Pharmacovigilance Expert Advisory Group. There are plausible mechanisms for an interaction between cocaine and citalopram that could lead

MHRA Drug Safety Update2016

5. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer`s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer`s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial 26771737 2016 05 02 2017 05 09 2017 05 09 1535-7228 173 5 2016 May 01 The American journal of psychiatry Am J Psychiatry Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. 465-72 10.1176/appi.ajp.2015.15050648 Pharmacological treatments (...) for agitation and aggression in patients with Alzheimer's disease have shown limited efficacy. The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed. In this double-blind parallel-group multicenter trial of 186 patients with Alzheimer's disease and clinically significant agitation, participants were randomly assigned to receive citalopram or placebo for 9 weeks, with the dosage

EvidenceUpdates2016

6. Pharmacological interventions: Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram

Pharmacological interventions: Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram Article Text Further commentaries Electronic pages Pharmacological interventions Lack of clinically

Evidence-Based Mental Health2016

7. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. OBJECTIVE: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function (...) , caregiver distress, safety, cognitive safety, and tolerability. DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013. INTERVENTIONS: Participants (n = 186) were randomized to receive a psychosocial

JAMA2014

8. Citalopram

Citalopram USE OF CITALOPRAM IN PREGNANCY 0344 892 0909 USE OF CITALOPRAM IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Citalopram is a selective serotonin reuptake inhibitor (SSRI) used (...) in the treatment of depression and panic disorder. Two studies have suggested that the risk of any major malformation is increased following maternal citalopram use in pregnancy, and a small number of studies have identified statistically significant increased risks of specific congenital malformations, including cardiac malformation. However, the majority of primary data studies and meta-analyses have failed to demonstrate a statistically significant increase in the risk of overall malformation

UK Teratology Information Service2014

9. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. 24549548 2014 02 19 2014 02 24 2016 12 15 1538-3598 311 7 2014 Feb 19 JAMA JAMA Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. 682-91 10.1001/jama.2014.93 Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. The primary (...) objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability. The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United

JAMA2014 Full Text: Link to full Text with Trip Pro

10. Randomised controlled trial: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Randomised controlled trial: Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects Article

Evidence-Based Medicine (Requires free registration)2014

11. Citalopram effective for major depression

Citalopram effective for major depression Citalopram effective for major depression | Cochrane Primary Care Top menu Trusted evidence. Informed decisions. Better health. Enter terms Citalopram effective for major depression Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2017 The Cochrane Collaboration | |

Cochrane PEARLS2013

12. Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs

Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs Article Text Therapeutics Review: short-term benefit of escitalopram versus citalopram

Evidence-Based Mental Health2013

13. Efficacy of escitalopram compared to citalopram: a meta-analysis

Efficacy of escitalopram compared to citalopram: a meta-analysis Efficacy of escitalopram compared to citalopram: a meta-analysis Efficacy of escitalopram compared to citalopram: a meta-analysis Montgomery S, Hansen T, Kasper S CRD summary The review concluded that there was a statistically and clinically significant benefit with escitalopram compared with citalopram in patients with major depressive disorder. The review appeared to have some methodological limitations, and the quality (...) of the included trials is uncertain; hence, caution is warranted when interpreting the authors’ conclusions. Authors' objectives To assess the clinical relevance of the relative antidepressant efficacy of escitalopram and citalopram for the treatment of major depressive disorder. Searching MEDLINE (1966 to June 2009), EMBASE (1998 to 2009) and The Cochrane Library (1980 to June 2009) were searched for articles in any language. Search terms were reported. Reference lists of retrieved studies were searched

DARE.2012

14. Citalopram and escitalopram: QT interval prolongation

Citalopram and escitalopram: QT interval prolongation Citalopram and escitalopram: QT interval prolongation Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Citalopram and escitalopram: QT interval prolongation From: Published: 12 December 2011 Therapeutic area: New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Article date: December 2011 Citalopram, a racemic mixture of R and S citalopram (...) , is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, panic disorder, and obsessive compulsive disorder. Escitalopram is the S enantiomer of citalopram indicated for major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalised anxiety disorder, and obsessive compulsive disorder. New data for QT prolongation with citalopram and escitalopram The potential for citalopram and escitalopram to cause QT interval prolongation

MHRA Drug Safety Update2011

15. Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials

Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials Apler A CRD summary The review concluded that citalopram had a statistically significant advantage over placebo (...) with respect to symptom improvement and response rates in adults with major depressive disorder, but its role in symptom remission was less clear. The sub-optimal quality of the trials and small evidence base limit the reliability of the author’s results. Authors' objectives To assess the effectiveness of citalopram for major depressive disorder in adults. Searching Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, PsycINFO and MEDLINE were searched to February 2011. Search terms were

DARE.2011

16. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials

Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials Trkulja V CRD summary This review compared (...) the efficacy of equimolar doses of escitalopram and citalopram in patients with major depressive disorder. The author concluded that claims to the clinically relevant superiority of escitalopram over citalopram in the short-to-medium term were not supported. This conclusion reflected the variable evidence presented, but its reliability is unclear due to potential methodological shortcomings in the review process. Authors' objectives To compare the efficacy of equimolar escitalopram and citalopram

DARE.2010

17. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin

Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Article Text Aetiology Current use of venlafaxine not associated

Evidence-Based Mental Health2010

18. Citalopram not effective for repetitive behaviour in autistic spectrum disorders

Citalopram not effective for repetitive behaviour in autistic spectrum disorders Citalopram not effective for repetitive behaviour in autistic spectrum disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citalopram not effective for repetitive behaviour in autistic spectrum disorders Article Text Therapeutics Citalopram not effective for repetitive behaviour in autistic spectrum disorders Statistics from Altmetric.com No Altmetric data available for this article. Question Question: How effective and safe is citalopram treatment

Evidence-Based Mental Health2010

19. Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy

Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy Article Text Aetiology Increased risk of septal heart defects in newborns as a result of sertraline and citalopram intake during pregnancy Statistics from

Evidence-Based Mental Health2010

20. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism 19487623 2009 06 02 2009 06 09 2016 12 15 1538-3636 66 6 2009 Jun Archives of general psychiatry Arch. Gen. Psychiatry Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. 583-90 10.1001/archgenpsychiatry.2009.30 (...) Selective serotonin reuptake inhibitors are widely prescribed for children with autism spectrum disorders. To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders. National Institutes of Health-sponsored randomized controlled trial. Six academic centers, including Mount Sinai School of Medicine, North Shore-Long Island Jewish Health System, University of North Carolina at Chapel Hill, University of California at Los Angeles, Yale University

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro